Supplementary Table S1. Overview of circulating EV-associated biomarkers for selected solid tumor entities tested in a clinical setting. Listed are protein-, RNA-, and DNA-based biomarkers that were clinically assessed in patient cohorts suffering from glioblastoma multiforme (GBM), head and neck cancer (HNC), lung cancer (LC), breast cancer (BC), hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC), prostate cancer (PC) and osteosarcoma (OS).

Type	Cancer entity	Biomarker	Clinical impact	Reference
Protein-based biomarkers	GBM	CD63, EGFR, EGFRvIII	Decrease after chemotherapy	Shao et al., 2012 [121]
	PDAC	CKAP4	Decrease after resection	Kimura et al., 2019 [119]
		EpCAM	High levels predict worse survival	Giampieri et al., 2019 [124]
	CRC	CD147	Decrease after resection	Yoshioka et al., 2014 [116]
		EGFR	High levels predict worse survival	Menck et al., 2017 [23]
		GPC1	Decrease after resection	Li et al., 2017 [118]
		CPNE3	High levels predict worse survival, diagnostic relevance	Sun et al., 2019 [95]
		Hsp60	Decrease after resection	Campanella et al., 2015 [117]
	LC	MUC1	High levels predict worse survival	Menck et al., 2017 [23]
		EGFR	Increased levels in patients	Yamashita et al., 2013 [94]
		19 proteins	Increased levels in patients, diagnostic relevance	Hoshino et al., 2020 [98]
	PC	PSMA	Decrease after prostatectomy	Biggs et al., 2016 [120]
		PSA	Increased levels in patients, diagnostic relevance	Logozzi et al., 2019 [100]
		Survivin	Increased levels in patients	Khan et al., 2012 [101]
		51 proteins	Increased levels in patients, diagnostic relevance	Hoshino et al., 2020 [98]
	BC	Del-1	Decrease after resection	Moon et al., 2016 [102]
		Survivin	Increased levels in patients, diagnostic relevance	Khan et al., 2014 [93]
		CD82	Expression correlates with disease progression	Wang et al., 2019 [97]
		MUC1, EpCAM	High levels predict worse survival	Menck et al., 2017 [23]
	HNC	MUC1, EpCAM	High levels predict worse survival	Menck et al., 2017 [23]
		CD3, PDL1 (T_{reg} -derived	Increase in patients with recurrence	Theodoraki et al., 2019 [82]
	HCC	miR-1247-3p	High levels associated with lung metastasis	Fang et al., 2018 [136]

RNA-based biomarkers		miR-638	Low levels associated with shortend survival	Shi et al., 2018 [138]
	PDAC	lncRNA HULC	Increased in patients	Takahashi et al., 2020 [103]
		miR-21	High levels associated with shortend survival	Goto et al., 2018 [104]
	CRC	ΔNp73 mRNA	High levels associated with shortend survival	Soldevilla et al., 2014 [96]
		lncRNA CRNDE-p	Decrease after chemotherapy	Yu et al., 2017 [139]
		miR-217	Increase after chemotherapy	Yu et al., 2017 [139]
		miR-17-5p, miR-92a-3p	High levels associated with disease progression	Fu et al., 2018 [137]
	LC	miR-23b-3p, miR-10b-5p, miR-21-5p	High levels associated with shortend survival	Liu et al., 2017 [105]
		miR-425–3p	High levels predict worse survival after chemotherapy	Yuwen et al., 2019 [130]
		miR-146a-5p	Low levels predict recurrence after chemotherapy	Yuwen et al., 2017 [134]
		hsa-miR-320b, -c, -d	High levels in non-responders to anti-PD-1 therapy	Peng et al., 2020 [128]
		PD-L1 mRNA	High levels in responders to anti-PD-1 therapy	Del Re et al., 2018 [127]
	PC	hsa-let-7a-5p	Increase after radiation therapy	Malla et al., 2018 [80]
		miR-654-3p, miR379-5p	Predict efficacy of radiotherapy	Yu et al., 2018 [133]
	BC	miR-301, miR-155	Decrease after neoadjuvant chemotherapy	Stevic et al., 2018 [122]
		miR-21	High levels correlate with tumor size and CTC concentration	Rodriguez-Martinez et al., 2019 [106]
		lncRNA HOTAIR	Decrease after resection	Tang et al., 2019 [123]
	OS	Transcriptomic profile	Metastatic signature	Bao et al., 2018 [135]
		RNA mutation burden	Increase upon metastasis	Bao et al., 2018 [135]
DNA-based biomarkers	PDAC	KRAS mutation	High detection rates correlate with disease progression and survival	Allenson et al., 2017 [107]
	GBM	IDH1 mutation	Decreased detection in low-grade gliomas	Garcia-Romero et al., 2017 [140]
	LC	EGFR mutation	High detection efficiency when combined with cfDNA	Castellanos-Rizaldos et al., 2019 [112]
	CRC	Several mutations	Detection rates correlate with tumor size	Thakur et al., 2021 [109]